Retrophin neurological disorder drug misses late-stage study main goal

Aug 22 (Reuters) - Retrophin Inc said on Thursday its treatment for a rare neurological disorder failed to meet the main goal in a late-stage study.

   The treatment, fosmetpantotenate, was being tested in 84 patients with pantothenate kinase-associated neurodegeneration, a rare, genetic and life-threatening disorder.

   The treatment, tested against placebo, also failed to meet its secondary goal, the company said.

(Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by

Shinjini Ganguli)

((Aakash.B@thomsonreuters.com; within the U.S. +16462238780,

outside the U.S. +91 80 67491576; Twitter: @JagadeeshAakash;)